Patología vascular: ¿causa o efecto en la enfermedad de Alzheimer?

Kumar, 2010 Seeley, 2012, Dementia, 3300 Ferri, 2005, Global prevalence of dementia: A Delphi consensus study, Lancet., 366, 2112, 10.1016/S0140-6736(05)67889-0 Gascon-Bayarri, 2007, Prevalence of dementia subtypes in el Prat de Llobregat, Catalonia, Spain: the PRATICON study, Neuroepidemiology., 28, 224, 10.1159/000108597 2015 Alzheimer, 1995, An English translation of Alzheimer's 1907 paper, uber eine eigenartige erkankung der hirnrinde, Clin Anat., 8, 429, 10.1002/ca.980080612 Maurer, 1997, Auguste D and Alzheimer's disease, Lancet., 349, 1546, 10.1016/S0140-6736(96)10203-8 Glenner, 1984, Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochem Biophys Res Commun., 120, 885, 10.1016/S0006-291X(84)80190-4 Goldgaber, 1987, Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease, Science., 235, 877, 10.1126/science.3810169 Goate, 1991, Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease, Nature., 349, 704, 10.1038/349704a0 Hardy, 1992, Alzheimer's disease: The amyloid cascade hypothesis, Science., 256, 184, 10.1126/science.1566067 Tanzi, 2005, Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective, Cell., 120, 545, 10.1016/j.cell.2005.02.008 Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics, Science., 297, 353, 10.1126/science.1072994 Hussain, 1999, Identification of a novel aspartic protease (asp 2) as beta-secretase, Mol Cell Neurosci., 14, 419, 10.1006/mcne.1999.0811 Vassar, 1999, Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE, Science., 286, 735, 10.1126/science.286.5440.735 Sherrington, 1995, Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease, Nature., 375, 754, 10.1038/375754a0 Levy-Lahad, 1995, Candidate gene for the chromosome 1 familial Alzheimer's disease locus, Science., 269, 973, 10.1126/science.7638622 Wolfe, 1999, Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity, Nature., 398, 513, 10.1038/19077 Ballard, 2011, Alzheimer's disease, Lancet., 377, 1019, 10.1016/S0140-6736(10)61349-9 O’Brien, 2011, Amyloid precursor protein processing and Alzheimer's disease, Annu Rev Neurosci., 34, 185, 10.1146/annurev-neuro-061010-113613 LaFerla, 2007, Intracellular amyloid-beta in Alzheimer's disease, Nat Rev Neurosci., 8, 499, 10.1038/nrn2168 Bergmans, 2010, Gamma-secretases. From cell biology to therapeutic strategies, Lancet Neurol., 9, 215, 10.1016/S1474-4422(09)70332-1 Alonso Vilatela, 2012, Genetics of Alzheimer's disease, Arch Med Res., 43, 622, 10.1016/j.arcmed.2012.10.017 Karran, 2011, The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics, Nat Rev Drug Discov., 10, 698, 10.1038/nrd3505 Tiraboschi, 2004, Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease, Neurology., 62, 1977, 10.1212/01.WNL.0000128091.92139.0F Grundke-Iqbal, 1986, Microtubule-associated protein tau. A component of Alzheimer paired helical filaments, J Biol Chem., 261, 6084, 10.1016/S0021-9258(17)38495-8 Brunden, 2009, Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies, Nat Rev Drug Discov., 8, 783, 10.1038/nrd2959 De la Torre, 1993, Can disturbed brain microcirculation cause Alzheimer's disease?, Neurol Res., 15, 146, 10.1080/01616412.1993.11740127 Gentleman, 1993, Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury, Neurosci Lett., 160, 139, 10.1016/0304-3940(93)90398-5 Davis, 1999, Alzheimer neuropathologic alterations in aged cognitively normal subjects, J Neuropathol Exp Neurol., 58, 376, 10.1097/00005072-199904000-00008 Launer, 2000, Midlife blood pressure and dementia: The Honolulu-Asia aging study, Neurobiol Aging., 21, 49, 10.1016/S0197-4580(00)00096-8 Kivipelto, 2001, Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study, BMJ., 322, 1447, 10.1136/bmj.322.7300.1447 Xu, 2011, Midlife overweight and obesity increase late-life dementia risk: A population-based twin study, Neurology., 76, 1568, 10.1212/WNL.0b013e3182190d09 Luchsinger, 2009, Adiposity, type 2 diabetes, and Alzheimer's disease, J Alzheimers Dis., 16, 693, 10.3233/JAD-2009-1022 Domínguez, 2014, Enfermedad de Alzheimer y deterioro cognitivo asociado a la diabetes mellitus de tipo 2: relaciones e hipótesis, Neurologia., 29, 567, 10.1016/j.nrl.2013.05.006 Ott, 1999, Diabetes mellitus and the risk of dementia: The Rotterdam study, Neurology., 53, 1937, 10.1212/WNL.53.9.1937 Kopf, 2009, Risk of incident Alzheimer's disease in diabetic patients: A systematic review of prospective trials, J Alzheimers Dis., 16, 677, 10.3233/JAD-2009-1011 Hofman, 1997, Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study, Lancet., 349, 151, 10.1016/S0140-6736(96)09328-2 Rodrigue, 2013, Risk factors for beta-amyloid deposition in healthy aging: Vascular and genetic effects, JAMA Neurol., 70, 600, 10.1001/jamaneurol.2013.1342 Zlokovic, 2008, The blood-brain barrier in health and chronic neurodegenerative disorders, Neuron., 57, 178, 10.1016/j.neuron.2008.01.003 Zlokovic, 2011, Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders, Nat Rev Neurosci., 12, 723, 10.1038/nrn3114 Mooradian, 1997, GLUT-1 expression in the cerebra of patients with Alzheimer's disease, Neurobiol Aging., 18, 469, 10.1016/S0197-4580(97)00111-5 Choi, 2014, Increased expression of the receptor for advanced glycation end products in neurons and astrocytes in a triple transgenic mouse model of Alzheimer's disease, Exp Mol Med., 46, e75, 10.1038/emm.2013.147 Zlokovic, 2004, Clearing amyloid through the blood-brain barrier, J Neurochem., 89, 807, 10.1111/j.1471-4159.2004.02385.x Mawuenyega, 2010, Decreased clearance of CNS beta-amyloid in Alzheimer's disease, Science., 330, 1774, 10.1126/science.1197623 Sagare, 2012, Low-density lipoprotein receptor-related protein 1: A physiological Aβ homeostatic mechanism with multiple therapeutic opportunities, Pharmacol Ther., 136, 94, 10.1016/j.pharmthera.2012.07.008 Shibata, 2000, Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier, J Clin Invest., 106, 1489, 10.1172/JCI10498 Deane, 2004, LRP/amyloid beta-peptide interaction mediates differential brain efflux of abeta isoforms, Neuron., 43, 333, 10.1016/j.neuron.2004.07.017 Owen, 2010, Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: Implications for Aβ accumulation in AD brain, Free Radic Biol Med., 49, 1798, 10.1016/j.freeradbiomed.2010.09.013 Deane, 2008, apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain, J Clin Invest., 118, 4002, 10.1172/JCI36663 Liu, 2007, Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1, Neuron., 56, 66, 10.1016/j.neuron.2007.08.008 Johnson, 2000, Perfusion abnormalities in prodromal AD, Neurobiol Aging., 21, 289, 10.1016/S0197-4580(00)00137-8 Zhao, 2015, From chronic cerebral hypoperfusion to Alzheimer-like brain pathology and neurodegeneration, Cell Mol Neurobiol., 35, 101, 10.1007/s10571-014-0127-9 De la Torre, 2002, Vascular basis of Alzheimer's pathogenesis, Ann N Y Acad Sci., 977, 196, 10.1111/j.1749-6632.2002.tb04817.x Zlokovic, 2005, Neurovascular mechanisms of Alzheimer's neurodegeneration, Trends Neurosci., 28, 202, 10.1016/j.tins.2005.02.001 Zhang, 2007, Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation, J Biol Chem., 282, 10873, 10.1074/jbc.M608856200 Marshall, 2006, Chronic hypoxia in the human neuroblastoma SH-SY5Y causes reduced expression of the putative alpha-secretases, ADAM10 and TACE, without altering their mRNA levels, Brain Res., 1099, 18, 10.1016/j.brainres.2006.05.008 Kelleher, 2013, Evidence of endothelial dysfunction in the development of Alzheimer's disease: Is Alzheimer's a vascular disorder?, Am J Cardiovasc Dis., 3, 197 Wakita, 1992, Regional accumulation of amyloid beta/A4 protein precursor in the gerbil brain following transient cerebral ischemia, Neurosci Lett., 146, 135, 10.1016/0304-3940(92)90061-B Kitaguchi, 2009, Chronic cerebral hypoperfusion accelerates amyloid beta deposition in APPSwInd transgenic mice, Brain Res., 1294, 202, 10.1016/j.brainres.2009.07.078 Deane, 2003, RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain, Nat Med., 9, 907, 10.1038/nm890 Austin, 2010, Endothelial nitric oxide modulates expression and processing of amyloid precursor protein, Circ Res., 107, 1498, 10.1161/CIRCRESAHA.110.233080 Grammas, 2011, Neurovascular dysfunction, inflammation and endothelial activation: Implications for the pathogenesis of Alzheimer's disease, J Neuroinflammation., 8, 26, 10.1186/1742-2094-8-26 Zhao, 2011, The contribution of activated astrocytes to Abeta production: Implications for Alzheimer's disease pathogenesis, J Neuroinflammation., 8, 150, 10.1186/1742-2094-8-150 Li, 2009, Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier, J Immunol., 182, 5778, 10.4049/jimmunol.0803013 Galimberti, 2011, Disease-modifying treatments for Alzheimer's disease, Ther Adv Neurol Disord., 4, 203, 10.1177/1756285611404470 McGeer, 1996, Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies, Neurology., 47, 425, 10.1212/WNL.47.2.425 Hayden, 2007, Does NSAID use modify cognitive trajectories in the elderly? The Cache County study, Neurology., 69, 275, 10.1212/01.wnl.0000265223.25679.2a Yan, 2003, Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease, J Neurosci., 23, 7504, 10.1523/JNEUROSCI.23-20-07504.2003 Aisen, 2003, Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial, JAMA., 289, 2819, 10.1001/jama.289.21.2819 Martin, 2008, Cognitive function over time in the Alzheimer's disease anti-inflammatory prevention trial (ADAPT): Results of a randomized, controlled trial of naproxen and celecoxib, Arch Neurol., 65, 896, 10.1001/archneur.2008.65.7.nct70006 Pasinetti, 2002, From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: The role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia, J Alzheimers Dis., 4, 435, 10.3233/JAD-2002-4510 Simons, 2002, Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial, Ann Neurol., 52, 346, 10.1002/ana.10292 Sano, 2011, A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease, Neurology., 77, 556, 10.1212/WNL.0b013e318228bf11 McGuinness, 2009, Statins for the prevention of dementia, Cochrane Database Syst Rev., 2, 10.1002/14651858.CD003160.pub2 Shinohara, 2010, Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance, J Biol Chem., 285, 22091, 10.1074/jbc.M110.102277 Li, 2006, Simvastatin enhances learning and memory independent of amyloid load in mice, Ann Neurol., 60, 729, 10.1002/ana.21053 Wanamaker, 2015, Cholesterol, statins, and dementia: What the cardiologist should know, Clin Cardiol., 38, 243, 10.1002/clc.22361 Forette, 1998, Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (syst-eur) trial, Lancet., 352, 1347, 10.1016/S0140-6736(98)03086-4 Yasar, 2013, Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo evaluation of memory study, Neurology., 81, 896, 10.1212/WNL.0b013e3182a35228 Ashby, 2013, Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease, Expert Opin Investig Drugs., 22, 1229, 10.1517/13543784.2013.812631 Zlokovic, 2008, New therapeutic targets in the neurovascular pathway in Alzheimer's disease, Neurotherapeutics., 5, 409, 10.1016/j.nurt.2008.05.011 Hong-Qi, 2012, Current advances in the treatment of Alzheimer's disease: Focused on considerations targeting Aβ and tau, Transl Neurodegener., 1, 21, 10.1186/2047-9158-1-21 Galasko, 2014, Clinical trial of an inhibitor of RAGE-abeta interactions in Alzheimer disease, Neurology., 82, 1536, 10.1212/WNL.0000000000000364